FRI0197 EFFICACY DATA OF MC2–03 (CICLOSPORIN 0.03% AND 0.06% EYEDROPS) IN SJOGREN’S PATIENTS WITH SEVERE KERATITIS: OUTCOMES OF THE NORTHERN LIGHTS PHASE 2B TRIAL
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.4246
Abstract: Background: Sjögren’s syndrome is one of the most common rheumatic autoimmune disorders (1). It is a chronic systemic autoimmune disease in which immunomediated inflammation, characterized by lymphocytic infiltration of exocrine glands and epithelia, causes secretory… read more here.
Keywords: sjogren patients; trial; cfs; efficacy ... See more keywords